Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

1987 • 2,769 citations

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

1982 • 2,228 citations

Randomized Comparisons of Radiotherapy and Nitrosoureas for the Treatment of Malignant Glioma after Surgery

1980 • 1,625 citations

Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

1981 • 516 citations

Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

1982 • 267 citations

Intratumoral LAK cell and interleukin-2 therapy of human gliomas

1989 • 252 citations

The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2

1986 • 145 citations

Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy

1991 • 108 citations

Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2

1988 • 106 citations

Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.

1988 • 98 citations

Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.

1987 • 91 citations

Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma

1986 • 89 citations

Immunotherapy with autologous white cell infusions (“lymphocytes”) in the treatment of recurrent glioblastoma multiforme.A preliminary report

1977 • 79 citations

In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes

1986 • 76 citations

Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor

1987 • 69 citations

Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality

1986 • 68 citations

Immunological aspects of intrinsic glial tumors

1981 • 68 citations

Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice.

1986 • 67 citations

Anti-ATLA (Antibody to the Adult T-Cell Leukemia Cell-Associated Antigen)-Positive Hematologic Malignancies in the Kanto District

1982 • 63 citations

Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2

1987 • 59 citations

Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: clinical and experimental studies

1986 • 35 citations

Adjuvant Immunotherapy for Malignant Brain Tumors

1972 • 32 citations

Salvage Immunotherapy of Malignant Glioma

1987 • 31 citations

THE DIFFERENTIAL INHIBITORY EFFECTS EXERTED BY CYCLOSPORINE AND HYDROCORTISONE ON THE ACTIVATION OF HUMAN CYTOTOXIC LYMPHOCYTES BY RECOMBINANT INTERLEUKIN-2 VERSUS ALLOSPECIFIC CTL

1985 • 30 citations

Intratumoral autologous mononuclear cells in the treatment of recurrent glioblastoma multiforme

1984 • 27 citations

Immunotherapy of Patients with Glioma: Fact, Fancy, and Future

2015 • 15 citations

Treatment of glioma with intratumoral instillation of autologous lymphocytes

1989 • 5 citations